Are integrins still practicable targets for anti-cancer therapy?

Begoña Alday-Parejo, Roger Stupp, Curzio Rüegg*

*Corresponding author for this work

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Correlative clinical evidence and experimental observations indicate that integrin adhesion receptors, in particular those of the αV family, are relevant to cancer cell features, including proliferation, survival, migration, invasion, and metastasis. In addition, integrins promote events in the tumor microenvironment that are critical for tumor progression and metastasis, including tumor angiogenesis, matrix remodeling, and the recruitment of immune and inflammatory cells. In spite of compelling preclinical results demonstrating that the inhibition of integrin αVβ3/αVβ5 and α5β1 has therapeutic potential, clinical trials with integrin inhibitors targeting those integrins have repeatedly failed to demonstrate therapeutic benefits in cancer patients. Here, we review emerging integrin functions and their proposed contribution to tumor progression, discuss preclinical evidence of therapeutic significance, revisit clinical trial results, and consider alternative approaches for their therapeutic targeting in oncology, including targeting integrins in the other cells of the tumor microenvironment, e.g., cancer-associated fibroblasts and immune/inflammatory cells. We conclude that integrins remain a valid target for cancer therapy; however, agents with better pharmacological properties, alternative models for their preclinical evaluation, and innovative combination strategies for clinical testing (e.g., together with immuno-oncology agents) are needed.

Original languageEnglish (US)
Article number978
JournalCancers
Volume11
Issue number7
DOIs
StatePublished - Jul 2019

Fingerprint

Integrins
Neoplasms
Tumor Microenvironment
Therapeutics
Clinical Trials
Neoplasm Metastasis
Cellular Microenvironment
Pharmacology
Survival

Keywords

  • Angiogenesis
  • Cancer
  • Imaging
  • Therapy
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Alday-Parejo, Begoña ; Stupp, Roger ; Rüegg, Curzio. / Are integrins still practicable targets for anti-cancer therapy?. In: Cancers. 2019 ; Vol. 11, No. 7.
@article{85c6750df5274b7b8c4094c850a58473,
title = "Are integrins still practicable targets for anti-cancer therapy?",
abstract = "Correlative clinical evidence and experimental observations indicate that integrin adhesion receptors, in particular those of the αV family, are relevant to cancer cell features, including proliferation, survival, migration, invasion, and metastasis. In addition, integrins promote events in the tumor microenvironment that are critical for tumor progression and metastasis, including tumor angiogenesis, matrix remodeling, and the recruitment of immune and inflammatory cells. In spite of compelling preclinical results demonstrating that the inhibition of integrin αVβ3/αVβ5 and α5β1 has therapeutic potential, clinical trials with integrin inhibitors targeting those integrins have repeatedly failed to demonstrate therapeutic benefits in cancer patients. Here, we review emerging integrin functions and their proposed contribution to tumor progression, discuss preclinical evidence of therapeutic significance, revisit clinical trial results, and consider alternative approaches for their therapeutic targeting in oncology, including targeting integrins in the other cells of the tumor microenvironment, e.g., cancer-associated fibroblasts and immune/inflammatory cells. We conclude that integrins remain a valid target for cancer therapy; however, agents with better pharmacological properties, alternative models for their preclinical evaluation, and innovative combination strategies for clinical testing (e.g., together with immuno-oncology agents) are needed.",
keywords = "Angiogenesis, Cancer, Imaging, Therapy, Tumor microenvironment",
author = "Bego{\~n}a Alday-Parejo and Roger Stupp and Curzio R{\"u}egg",
year = "2019",
month = "7",
doi = "10.3390/cancers11070978",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

Are integrins still practicable targets for anti-cancer therapy? / Alday-Parejo, Begoña; Stupp, Roger; Rüegg, Curzio.

In: Cancers, Vol. 11, No. 7, 978, 07.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Are integrins still practicable targets for anti-cancer therapy?

AU - Alday-Parejo, Begoña

AU - Stupp, Roger

AU - Rüegg, Curzio

PY - 2019/7

Y1 - 2019/7

N2 - Correlative clinical evidence and experimental observations indicate that integrin adhesion receptors, in particular those of the αV family, are relevant to cancer cell features, including proliferation, survival, migration, invasion, and metastasis. In addition, integrins promote events in the tumor microenvironment that are critical for tumor progression and metastasis, including tumor angiogenesis, matrix remodeling, and the recruitment of immune and inflammatory cells. In spite of compelling preclinical results demonstrating that the inhibition of integrin αVβ3/αVβ5 and α5β1 has therapeutic potential, clinical trials with integrin inhibitors targeting those integrins have repeatedly failed to demonstrate therapeutic benefits in cancer patients. Here, we review emerging integrin functions and their proposed contribution to tumor progression, discuss preclinical evidence of therapeutic significance, revisit clinical trial results, and consider alternative approaches for their therapeutic targeting in oncology, including targeting integrins in the other cells of the tumor microenvironment, e.g., cancer-associated fibroblasts and immune/inflammatory cells. We conclude that integrins remain a valid target for cancer therapy; however, agents with better pharmacological properties, alternative models for their preclinical evaluation, and innovative combination strategies for clinical testing (e.g., together with immuno-oncology agents) are needed.

AB - Correlative clinical evidence and experimental observations indicate that integrin adhesion receptors, in particular those of the αV family, are relevant to cancer cell features, including proliferation, survival, migration, invasion, and metastasis. In addition, integrins promote events in the tumor microenvironment that are critical for tumor progression and metastasis, including tumor angiogenesis, matrix remodeling, and the recruitment of immune and inflammatory cells. In spite of compelling preclinical results demonstrating that the inhibition of integrin αVβ3/αVβ5 and α5β1 has therapeutic potential, clinical trials with integrin inhibitors targeting those integrins have repeatedly failed to demonstrate therapeutic benefits in cancer patients. Here, we review emerging integrin functions and their proposed contribution to tumor progression, discuss preclinical evidence of therapeutic significance, revisit clinical trial results, and consider alternative approaches for their therapeutic targeting in oncology, including targeting integrins in the other cells of the tumor microenvironment, e.g., cancer-associated fibroblasts and immune/inflammatory cells. We conclude that integrins remain a valid target for cancer therapy; however, agents with better pharmacological properties, alternative models for their preclinical evaluation, and innovative combination strategies for clinical testing (e.g., together with immuno-oncology agents) are needed.

KW - Angiogenesis

KW - Cancer

KW - Imaging

KW - Therapy

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85071362388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071362388&partnerID=8YFLogxK

U2 - 10.3390/cancers11070978

DO - 10.3390/cancers11070978

M3 - Review article

C2 - 31336983

AN - SCOPUS:85071362388

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 7

M1 - 978

ER -